MAP2K3
MOLECULAR TARGETmitogen-activated protein kinase kinase 3
MAP2K3 (mitogen-activated protein kinase kinase 3) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MAP2K3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | alvocidib | 4.52 | 91 |
| 2 | ruxolitinib | 4.23 | 68 |
| 3 | bosutinib | 4.08 | 58 |
| 4 | midostaurin | 3.85 | 46 |
| 5 | nintedanib | 3.61 | 36 |
| 6 | tae 684 | 3.43 | 30 |
| 7 | fedratinib | 3.40 | 29 |
| 8 | jnj 7706621 | 3.09 | 21 |
| 9 | lestaurtinib | 3.04 | 20 |
| 10 | r 406 | 2.83 | 16 |
| 11 | kw 2449 | 2.64 | 13 |
| 12 | ast 487 | 2.56 | 12 |
| 13 | ripasudil | 2.40 | 10 |
| 14 | su 014813 | 2.20 | 8 |
| 15 | tg100 115 | 2.08 | 7 |
| 16 | Crizotinib | 0.69 | 1 |
About MAP2K3 as a Drug Target
MAP2K3 (mitogen-activated protein kinase kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented MAP2K3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MAP2K3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.